vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Rocket Lab Corp的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.2倍（$179.7M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -29.5%，领先64.0%），Rocket Lab Corp同比增速更快（35.7% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 24.5%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
CPRX vs RKLB — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $179.7M |
| 净利润 | $52.7M | $-52.9M |
| 毛利率 | 82.9% | 38.0% |
| 营业利润率 | 40.5% | -28.4% |
| 净利率 | 34.5% | -29.5% |
| 营收同比 | 7.6% | 35.7% |
| 净利润同比 | -5.8% | -1.1% |
| 每股收益（稀释后） | $0.40 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $179.7M | ||
| Q3 25 | $148.4M | $155.1M | ||
| Q2 25 | $146.6M | $144.5M | ||
| Q1 25 | $141.4M | $122.6M | ||
| Q4 24 | $141.8M | $132.4M | ||
| Q3 24 | $128.7M | $104.8M | ||
| Q2 24 | $122.7M | $106.3M | ||
| Q1 24 | $98.5M | $92.8M |
| Q4 25 | $52.7M | $-52.9M | ||
| Q3 25 | $52.8M | $-18.3M | ||
| Q2 25 | $52.1M | $-66.4M | ||
| Q1 25 | $56.7M | $-60.6M | ||
| Q4 24 | $55.9M | $-52.3M | ||
| Q3 24 | $43.9M | $-51.9M | ||
| Q2 24 | $40.8M | $-41.6M | ||
| Q1 24 | $23.3M | $-44.3M |
| Q4 25 | 82.9% | 38.0% | ||
| Q3 25 | 84.7% | 37.0% | ||
| Q2 25 | 85.9% | 32.1% | ||
| Q1 25 | 87.3% | 28.8% | ||
| Q4 24 | 84.7% | 27.8% | ||
| Q3 24 | 85.0% | 26.7% | ||
| Q2 24 | 87.4% | 25.6% | ||
| Q1 24 | 87.3% | 26.1% |
| Q4 25 | 40.5% | -28.4% | ||
| Q3 25 | 44.7% | -38.0% | ||
| Q2 25 | 45.2% | -41.3% | ||
| Q1 25 | 44.8% | -48.3% | ||
| Q4 24 | 44.3% | -38.9% | ||
| Q3 24 | 39.6% | -49.5% | ||
| Q2 24 | 44.2% | -40.7% | ||
| Q1 24 | 27.5% | -46.4% |
| Q4 25 | 34.5% | -29.5% | ||
| Q3 25 | 35.6% | -11.8% | ||
| Q2 25 | 35.6% | -46.0% | ||
| Q1 25 | 40.1% | -49.5% | ||
| Q4 24 | 39.4% | -39.5% | ||
| Q3 24 | 34.1% | -49.6% | ||
| Q2 24 | 33.2% | -39.2% | ||
| Q1 24 | 23.6% | -47.7% |
| Q4 25 | $0.40 | $-0.09 | ||
| Q3 25 | $0.42 | $-0.03 | ||
| Q2 25 | $0.41 | $-0.13 | ||
| Q1 25 | $0.45 | $-0.12 | ||
| Q4 24 | $0.44 | $-0.11 | ||
| Q3 24 | $0.35 | $-0.10 | ||
| Q2 24 | $0.33 | $-0.08 | ||
| Q1 24 | $0.19 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $954.3M | $1.7B |
| 总资产 | $1.1B | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $1.0B | ||
| Q3 25 | $689.9M | $976.7M | ||
| Q2 25 | $652.8M | $688.1M | ||
| Q1 25 | $580.7M | $428.4M | ||
| Q4 24 | $517.6M | $419.0M | ||
| Q3 24 | $442.3M | $442.4M | ||
| Q2 24 | $375.7M | $496.8M | ||
| Q1 24 | $310.4M | $492.5M |
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
| Q4 25 | $954.3M | $1.7B | ||
| Q3 25 | $920.2M | $1.3B | ||
| Q2 25 | $856.0M | $688.5M | ||
| Q1 25 | $794.3M | $431.3M | ||
| Q4 24 | $727.6M | $382.5M | ||
| Q3 24 | $660.9M | $419.8M | ||
| Q2 24 | $608.7M | $455.2M | ||
| Q1 24 | $561.4M | $478.9M |
| Q4 25 | $1.1B | $2.3B | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $971.9M | $1.6B | ||
| Q1 25 | $908.9M | $1.3B | ||
| Q4 24 | $851.4M | $1.2B | ||
| Q3 24 | $772.0M | $1.2B | ||
| Q2 24 | $706.4M | $1.2B | ||
| Q1 24 | $646.7M | $1.2B |
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $-114.2M |
| 自由现金流率自由现金流/营收 | 29.4% | -63.6% |
| 资本支出强度资本支出/营收 | 0.0% | 27.6% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $-321.8M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $-64.5M | ||
| Q3 25 | $32.4M | $-23.5M | ||
| Q2 25 | $71.3M | $-23.2M | ||
| Q1 25 | $60.0M | $-54.2M | ||
| Q4 24 | $70.9M | $-2.4M | ||
| Q3 24 | $72.9M | $-30.9M | ||
| Q2 24 | $64.1M | $-13.0M | ||
| Q1 24 | $31.9M | $-2.6M |
| Q4 25 | $44.9M | $-114.2M | ||
| Q3 25 | — | $-69.4M | ||
| Q2 25 | $71.3M | $-55.3M | ||
| Q1 25 | — | $-82.9M | ||
| Q4 24 | $70.8M | $-23.9M | ||
| Q3 24 | $72.6M | $-41.9M | ||
| Q2 24 | $64.1M | $-28.3M | ||
| Q1 24 | $31.7M | $-21.8M |
| Q4 25 | 29.4% | -63.6% | ||
| Q3 25 | — | -44.8% | ||
| Q2 25 | 48.6% | -38.3% | ||
| Q1 25 | — | -67.6% | ||
| Q4 24 | 49.9% | -18.1% | ||
| Q3 24 | 56.4% | -40.0% | ||
| Q2 24 | 52.3% | -26.7% | ||
| Q1 24 | 32.2% | -23.5% |
| Q4 25 | 0.0% | 27.6% | ||
| Q3 25 | 0.0% | 29.6% | ||
| Q2 25 | 0.0% | 22.2% | ||
| Q1 25 | 0.0% | 23.4% | ||
| Q4 24 | 0.1% | 16.3% | ||
| Q3 24 | 0.2% | 10.5% | ||
| Q2 24 | 0.0% | 14.4% | ||
| Q1 24 | 0.2% | 20.7% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
